Jeollanam-do

The trials here

What the trial at this site is about, from its registry record.

Conditions

• Gastric and oesophageal cancer

Running trials

• Active, not recruiting

  A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).

  NCT03653507· Phase 3· Astellas Pharma Global Development, Inc.· Source